Literature DB >> 15767245

Enhanced antithrombotic effect of warfarin associated with low-dose alcohol consumption.

Dawn E Havrda1, Tien Mai, Jennifer Chonlahan.   

Abstract

A 58-year-old Caucasian man was receiving long-term anticoagulation with warfarin for the prevention of ischemic stroke; his international normalized ratio (INR) had been stable. His INR increased when he began consistent, low-dose beer consumption for its perceived cardiovascular protection. After he stopped drinking the alcohol, his anticoagulation control improved and returned to previous levels. Information on the effects of alcohol, particularly beer, is limited in nonalcoholic patients who receive warfarin therapy. This case reveals a potential for low-dose beer consumption to elevate INR. We propose that the increased antithrombotic effect of warfarin involved protein-binding interactions and decreased warfarin metabolism through the cytochrome P450 (CYP) enzyme system. Concurrent administration of aspirin and other drugs that are metabolized through or are inhibitors of the CYP system may have enhanced the interaction that occurred in this patient. Caution should be used whenever warfarin and alcohol in any amount are taken together, especially in patients receiving many drugs, and close monitoring of the INR is warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15767245     DOI: 10.1592/phco.25.2.303.56955

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  8 in total

Review 1.  Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol).

Authors:  Lingtak-Neander Chan; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

2.  Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting.

Authors:  Joshua A Roth; Katharine Bradley; Kenneth E Thummel; David L Veenstra; Denise Boudreau
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-04-08       Impact factor: 2.890

3.  Identifying the risks of anticoagulation in patients with substance abuse.

Authors:  Lydia M Efird; Donald R Miller; Arlene S Ash; Dan R Berlowitz; Al Ozonoff; Shibei Zhao; Joel I Reisman; Guneet K Jasuja; Adam J Rose
Journal:  J Gen Intern Med       Date:  2013-04-26       Impact factor: 5.128

4.  Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.

Authors:  N A Limdi; G McGwin; J A Goldstein; T M Beasley; D K Arnett; B K Adler; M F Baird; R T Acton
Journal:  Clin Pharmacol Ther       Date:  2007-07-25       Impact factor: 6.875

5.  Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans.

Authors:  Na Limdi; Ja Goldstein; Ja Blaisdell; Tm Beasley; Ca Rivers; Rt Acton
Journal:  Per Med       Date:  2007-05-01       Impact factor: 2.512

6.  Effect of patient-specific factors on weekly warfarin dose.

Authors:  Heather P Whitley; Joli D Fermo; Elinor Cg Chumney; Walter Adam Brzezinski
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

Review 7.  Therapeutic drug monitoring in a developing nation: a clinical guide.

Authors:  Ndubuisi Nwobodo
Journal:  JRSM Open       Date:  2014-07-08

8.  A novel algorithm for analyzing drug-drug interactions from MEDLINE literature.

Authors:  Yin Lu; Dan Shen; Maxwell Pietsch; Chetan Nagar; Zayd Fadli; Hong Huang; Yi-Cheng Tu; Feng Cheng
Journal:  Sci Rep       Date:  2015-11-27       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.